JP2020522691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522691A5 JP2020522691A5 JP2019566134A JP2019566134A JP2020522691A5 JP 2020522691 A5 JP2020522691 A5 JP 2020522691A5 JP 2019566134 A JP2019566134 A JP 2019566134A JP 2019566134 A JP2019566134 A JP 2019566134A JP 2020522691 A5 JP2020522691 A5 JP 2020522691A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- lag
- cancer
- pharmaceutical composition
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 238000000034 method Methods 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 239000012634 fragment Substances 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 15
- 102000017578 LAG3 Human genes 0.000 claims 13
- 101150030213 Lag3 gene Proteins 0.000 claims 13
- 238000011282 treatment Methods 0.000 claims 13
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 11
- 230000037361 pathway Effects 0.000 claims 11
- 238000009169 immunotherapy Methods 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 229940122004 CD47 antagonist Drugs 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 229940125570 FS118 Drugs 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 229940125568 MGD013 Drugs 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229940123387 PVRIG antagonist Drugs 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 229940125566 REGN3767 Drugs 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940125564 Sym022 Drugs 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 229940125567 TSR-033 Drugs 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003236 esophagogastric junction Anatomy 0.000 claims 1
- 229940124981 favezelimab Drugs 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940121569 ieramilimab Drugs 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 238000011519 second-line treatment Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023111620A JP2023139047A (ja) | 2017-05-30 | 2023-07-06 | Ｌａｇ－３陽性腫瘍の処置 |
| JP2025097456A JP2025134762A (ja) | 2017-05-30 | 2025-06-11 | Ｌａｇ－３陽性腫瘍の処置 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512648P | 2017-05-30 | 2017-05-30 | |
| US62/512,648 | 2017-05-30 | ||
| US201762513813P | 2017-06-01 | 2017-06-01 | |
| US62/513,813 | 2017-06-01 | ||
| US201762555176P | 2017-09-07 | 2017-09-07 | |
| US62/555,176 | 2017-09-07 | ||
| US201762582178P | 2017-11-06 | 2017-11-06 | |
| US62/582,178 | 2017-11-06 | ||
| PCT/US2018/035134 WO2018222718A1 (en) | 2017-05-30 | 2018-05-30 | Treatment of lag-3 positive tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111620A Division JP2023139047A (ja) | 2017-05-30 | 2023-07-06 | Ｌａｇ－３陽性腫瘍の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522691A JP2020522691A (ja) | 2020-07-30 |
| JP2020522691A5 true JP2020522691A5 (enExample) | 2021-07-26 |
Family
ID=62778996
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566134A Pending JP2020522691A (ja) | 2017-05-30 | 2018-05-30 | Ｌａｇ−３陽性腫瘍の処置 |
| JP2023111620A Pending JP2023139047A (ja) | 2017-05-30 | 2023-07-06 | Ｌａｇ－３陽性腫瘍の処置 |
| JP2025097456A Pending JP2025134762A (ja) | 2017-05-30 | 2025-06-11 | Ｌａｇ－３陽性腫瘍の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111620A Pending JP2023139047A (ja) | 2017-05-30 | 2023-07-06 | Ｌａｇ－３陽性腫瘍の処置 |
| JP2025097456A Pending JP2025134762A (ja) | 2017-05-30 | 2025-06-11 | Ｌａｇ－３陽性腫瘍の処置 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11807686B2 (enExample) |
| EP (2) | EP4306542A3 (enExample) |
| JP (3) | JP2020522691A (enExample) |
| KR (3) | KR20240146108A (enExample) |
| CN (1) | CN110720039A (enExample) |
| AU (2) | AU2018277824A1 (enExample) |
| BR (1) | BR112019020610A2 (enExample) |
| CA (1) | CA3060984A1 (enExample) |
| DK (1) | DK3631454T3 (enExample) |
| ES (1) | ES2965352T3 (enExample) |
| FI (1) | FI3631454T3 (enExample) |
| HR (1) | HRP20231457T1 (enExample) |
| HU (1) | HUE065242T2 (enExample) |
| IL (2) | IL322104A (enExample) |
| LT (1) | LT3631454T (enExample) |
| MX (2) | MX2019012032A (enExample) |
| PL (1) | PL3631454T3 (enExample) |
| PT (1) | PT3631454T (enExample) |
| RS (1) | RS64787B1 (enExample) |
| SI (1) | SI3631454T1 (enExample) |
| SM (1) | SMT202300418T1 (enExample) |
| WO (1) | WO2018222718A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| KR20250025039A (ko) * | 2017-07-20 | 2025-02-20 | 노파르티스 아게 | 항-lag-3 항체의 투여 요법 및 그의 용도 |
| KR20210040080A (ko) * | 2018-07-26 | 2021-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 lag-3 조합 요법 |
| BR112021008582A8 (pt) * | 2018-11-05 | 2023-02-07 | Merck Sharp & Dohme | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer |
| EP3876990A4 (en) * | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| CA3139003A1 (en) * | 2019-05-14 | 2020-11-19 | F-Star Therapeutics Limited | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| WO2021030156A1 (en) * | 2019-08-09 | 2021-02-18 | The Regents Of The University Of California | Compositions and methods for diagnosis and treatment of bladder cancer |
| WO2021055994A1 (en) * | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| WO2021079958A1 (ja) * | 2019-10-25 | 2021-04-29 | 第一三共株式会社 | 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ |
| US20220411499A1 (en) * | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| CN113616788A (zh) * | 2020-05-08 | 2021-11-09 | 勤浩医药（苏州）有限公司 | 抗lag-3抗体与shp-2抑制剂联合治疗肿瘤的用途 |
| EP4157879A4 (en) * | 2020-05-27 | 2024-06-19 | Agilent Technologies, Inc. | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) |
| CA3193421A1 (en) * | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| WO2023051621A1 (zh) * | 2021-09-29 | 2023-04-06 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
| CN114869877B (zh) * | 2022-01-26 | 2024-05-31 | 兰州大学 | 一种小分子化合物及其作为lag3蛋白抑制剂的应用 |
Family Cites Families (169)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1081681A (en) | 1910-08-31 | 1913-12-16 | Otis Elevator Co | Alternating-current-motor control. |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2281899T3 (es) | 1994-05-06 | 2007-10-01 | Institut Gustave Roussy | Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo. |
| CA2227334A1 (en) | 1995-07-21 | 1997-02-06 | Applied Research Systems Ars Holding N.V. | Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| AU2071597A (en) | 1996-03-07 | 1997-09-22 | Eastman Chemical Company | Near infrared fluorescent security thermal transfer printing and marking ribbons |
| IL130123A (en) | 1996-11-28 | 2007-07-24 | Roussy Inst Gustave | LAG-3 protein mutants, their expression, use and method of production |
| UA73270C2 (en) | 1996-11-29 | 2005-07-15 | Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted | |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| JP5004390B2 (ja) | 1999-08-23 | 2012-08-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 新規ｂ７−４分子およびその用途 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| CN1277843C (zh) | 2001-02-22 | 2006-10-04 | 巴斯德研究院 | 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具 |
| US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
| AU2002341752B2 (en) | 2001-09-19 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
| ATE519779T1 (de) | 2001-09-19 | 2011-08-15 | Roussy Inst Gustave | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| NZ535925A (en) | 2002-04-16 | 2008-06-30 | Genentech Inc | An isolated antibody that binds to a particular polypeptide |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| JP2006502116A (ja) | 2002-07-12 | 2006-01-19 | メダレックス， インク． | タンパク質の酸化分解を防ぐ方法及び組成物 |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| JP2006523226A (ja) | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | Ｔ細胞調節方法 |
| WO2005034733A2 (en) | 2003-10-08 | 2005-04-21 | North Shore-Long Island Jewish Research Institute | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| CN1956738B (zh) | 2004-01-09 | 2013-05-29 | 辉瑞大药厂 | MAdCAM抗体 |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| BRPI0513706A (pt) | 2004-07-20 | 2008-05-13 | Symphogen As | anticorpo policlonal recombinante anti-rhesus d e métodos de produção |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP1793858A4 (en) | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| KR20070083899A (ko) | 2004-10-01 | 2007-08-24 | 메다렉스, 인코포레이티드 | Ｃｄ30 양성 림프종의 치료 방법 |
| PT3428191T (pt) | 2004-10-06 | 2024-12-30 | Mayo Found Medical Education & Res | B7-h1 e tratamento do carcinona de células renais |
| US20080279865A1 (en) | 2005-03-23 | 2008-11-13 | Pfizer, Inc., Pfizer Products, Inc. | Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
| CN101490085A (zh) | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| EP3018144A1 (en) | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| AU2008232903B9 (en) | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| HUE029164T2 (hu) | 2007-09-14 | 2017-02-28 | Univ Brussel Vrije | Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
| CA2768204A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Gram-positive bacteria specific binding compounds |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5934203B2 (ja) | 2010-07-14 | 2016-06-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌモノクローナル抗体およびこの使用 |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
| US9790280B2 (en) | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| US9689876B2 (en) | 2012-05-02 | 2017-06-27 | New York University | Methods related to cancer treatment |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| SI2970464T1 (sl) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Intellectual Propety Development Limited | Anti-LAG-3 vezavni proteini |
| US9944992B2 (en) | 2013-03-15 | 2018-04-17 | The University Of Chicago | Methods and compositions related to T-cell activity |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CN105682683A (zh) | 2013-08-02 | 2016-06-15 | 阿杜罗生物科技控股有限公司 | 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激 |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| EP3084001A4 (en) | 2013-12-17 | 2017-07-12 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
| US20160312297A1 (en) | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists |
| KR102630750B1 (ko) | 2013-12-17 | 2024-01-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| SI3556775T1 (sl) | 2014-01-28 | 2022-02-28 | Bristol-Myers Squibb Company | Protitelesa proti-LAG-3 za zdravljenje hematoloških malignosti |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| AU2015259516B2 (en) | 2014-05-13 | 2020-05-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3 |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| RU2017119428A (ru) | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Enumeral Biomedical Holdings Inc | Anti-pd-1 antibodies |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| US20190041389A1 (en) | 2015-02-13 | 2019-02-07 | The University Of Queensland | Methods for classifying tumors and uses therefor |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| NZ735820A (en) | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| JP2018515474A (ja) | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| CA2990107A1 (en) * | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| EP3314020A1 (en) | 2015-06-29 | 2018-05-02 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| AR105444A1 (es) | 2015-07-22 | 2017-10-04 | Sorrento Therapeutics Inc | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| CN116333138A (zh) | 2015-07-30 | 2023-06-27 | 宏观基因有限公司 | Pd-1结合分子和其使用方法 |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| EP3331901A1 (en) | 2015-08-07 | 2018-06-13 | Pieris Pharmaceuticals GmbH | Novel fusion polypeptide specific for lag-3 and pd-1 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| FI3334763T3 (fi) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Uusia pd-l1-vasta-aineita |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| CN108699145A (zh) | 2015-09-02 | 2018-10-23 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| EP3365063B1 (en) | 2015-10-23 | 2024-04-24 | Novartis AG | Method of scoring a sample comprising tumor tissue |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| SG10201911035QA (en) | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| US20190330336A1 (en) | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| BR112018010172A2 (pt) * | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| US10969392B2 (en) | 2015-12-10 | 2021-04-06 | Vanderbilt University | Methods and systems for predicting response to immunotherapies for treatment of cancer |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| MX2018007406A (es) | 2015-12-16 | 2018-08-15 | Merck Sharp & Dohme | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. |
| EP3402512A4 (en) | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF |
| CN111491362B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| MA55697A (fr) | 2016-05-18 | 2022-02-23 | Boehringer Ingelheim Int | Molécules d'anticorps pour le traitement du cancer |
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| US11214620B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | Binding molecules binding PD-L1 and LAG-3 |
| HUE058657T2 (hu) | 2016-06-23 | 2022-09-28 | Jiangsu Hengrui Medicine Co | Lag-3 antitest, antigénkötõ fragmentuma és gyógyszerészeti alkalmazása |
| CN109790532B (zh) | 2016-08-15 | 2022-06-17 | 国立大学法人北海道大学 | 抗lag-3抗体 |
| JP2019529437A (ja) | 2016-09-20 | 2019-10-17 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法 |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| CN110088136A (zh) | 2016-10-13 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用基因表达签名预测黑素瘤中对于ctla4封锁的应答和耐药性的组合物和方法 |
| UA127050C2 (uk) | 2016-10-13 | 2023-03-29 | Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. | Ahtи-lag-3 антитіло i композиція, що містить його |
| TW201829462A (zh) | 2016-11-02 | 2018-08-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | 結合蛋白 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| NZ759517A (en) | 2017-04-27 | 2025-02-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| CN110621337B (zh) | 2017-05-10 | 2021-11-09 | 浙江时迈药业有限公司 | 抗lag3人单克隆抗体及其用途 |
| US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| BR112019018759A2 (pt) | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| KR20210040080A (ko) | 2018-07-26 | 2021-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 lag-3 조합 요법 |
| PL3866850T3 (pl) | 2018-10-19 | 2024-10-14 | Bristol-Myers Squibb Company | Terapia skojarzona czerniaka |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| CA3193421A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
-
2018
- 2018-05-30 HU HUE18735009A patent/HUE065242T2/hu unknown
- 2018-05-30 LT LTEPPCT/US2018/035134T patent/LT3631454T/lt unknown
- 2018-05-30 ES ES18735009T patent/ES2965352T3/es active Active
- 2018-05-30 BR BR112019020610-8A patent/BR112019020610A2/pt unknown
- 2018-05-30 KR KR1020247032471A patent/KR20240146108A/ko not_active Ceased
- 2018-05-30 EP EP23196582.3A patent/EP4306542A3/en not_active Withdrawn
- 2018-05-30 PT PT187350095T patent/PT3631454T/pt unknown
- 2018-05-30 JP JP2019566134A patent/JP2020522691A/ja active Pending
- 2018-05-30 SM SM20230418T patent/SMT202300418T1/it unknown
- 2018-05-30 EP EP18735009.5A patent/EP3631454B1/en active Active
- 2018-05-30 KR KR1020257038309A patent/KR20250165687A/ko active Pending
- 2018-05-30 AU AU2018277824A patent/AU2018277824A1/en not_active Abandoned
- 2018-05-30 CN CN201880036546.9A patent/CN110720039A/zh active Pending
- 2018-05-30 HR HRP20231457TT patent/HRP20231457T1/hr unknown
- 2018-05-30 RS RS20231032A patent/RS64787B1/sr unknown
- 2018-05-30 KR KR1020197038189A patent/KR102713203B1/ko active Active
- 2018-05-30 US US16/616,574 patent/US11807686B2/en active Active
- 2018-05-30 CA CA3060984A patent/CA3060984A1/en active Pending
- 2018-05-30 WO PCT/US2018/035134 patent/WO2018222718A1/en not_active Ceased
- 2018-05-30 MX MX2019012032A patent/MX2019012032A/es unknown
- 2018-05-30 IL IL322104A patent/IL322104A/en unknown
- 2018-05-30 SI SI201831006T patent/SI3631454T1/sl unknown
- 2018-05-30 FI FIEP18735009.5T patent/FI3631454T3/fi active
- 2018-05-30 DK DK18735009.5T patent/DK3631454T3/da active
- 2018-05-30 PL PL18735009.5T patent/PL3631454T3/pl unknown
-
2019
- 2019-08-30 IL IL26902719A patent/IL269027A/en unknown
- 2019-10-07 MX MX2024000054A patent/MX2024000054A/es unknown
-
2023
- 2023-07-06 JP JP2023111620A patent/JP2023139047A/ja active Pending
- 2023-08-18 US US18/451,990 patent/US12049503B2/en active Active
-
2024
- 2024-06-17 US US18/745,399 patent/US20250043006A1/en active Pending
-
2025
- 2025-01-15 AU AU2025200288A patent/AU2025200288A1/en active Pending
- 2025-06-11 JP JP2025097456A patent/JP2025134762A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522691A5 (enExample) | ||
| Cousin et al. | Molecular pathways: immune checkpoint antibodies and their toxicities | |
| Saglam et al. | PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer | |
| JP6970099B2 (ja) | ガンの処置のための方法及び医薬組成物 | |
| JP2021509009A5 (enExample) | ||
| US11292840B2 (en) | Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2020534250A5 (enExample) | ||
| JP2020528750A5 (enExample) | ||
| JP2018027952A5 (enExample) | ||
| HRP20231457T1 (hr) | Liječenje lag-3-pozitivnih tumora | |
| JP2016531849A (ja) | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ | |
| JP2020503273A5 (enExample) | ||
| JP2020522494A5 (enExample) | ||
| EP3307778A1 (en) | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways | |
| RU2019127550A (ru) | Анти-gitr антитела и способы их использования | |
| WO2014066532A1 (en) | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer | |
| RU2017121096A (ru) | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 | |
| CN113507963A (zh) | 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体 | |
| JP2021522211A (ja) | Ｅｐ４阻害剤およびその使用 | |
| TW201642897A (zh) | Ｈｅｒ２結合劑治療 | |
| JP2021532143A (ja) | 癌の処置のためのｌａｇ−３併用療法 | |
| JP2023521227A (ja) | 癌の併用療法 | |
| JPWO2020023707A5 (enExample) | ||
| US20210353750A1 (en) | Methods of Treating Cancer |